Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07825181) titled 'Homologous Recombination Repair Deficiency (HRD) Testing in Newly Diagnosed Advanced-stage Epithelial Ovarian Cancer in Italy' on Sept. 3.

Study Type: Observational

Primary Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Condition: Epithelial Ovarian Cancer

Intervention: Diagnostic Test: HRD test

Recruitment Status: Not recruiting

Date of First Enrollment: September 2026

Target Sample Size: 1125

Countries of Recruitment: Italy

To know more, visit https://clinicaltrials.gov/study/NCT07825181

Disclaimer: Curated by HT Syndication....